Wegener's Granulomatosis (WG)

Executive summary

Wegener's granulomatosis is a necrotizing granulomatous vasculitis with the prevalence of 3 in 100 000. The disease was first described in 1931 by a medical student in Germany named Heinz Klinger. Afterwards, in 1936 Dr. Wegener a young German pathologist gave a detailed explanation regarding three patients suffering from this disease.Although it is an uncommon disease, if not diagnosed and treated in-time my cause renal failure and severe pulmonary complications including diffuse pulmonary hemorrhage. Therefore, timely diagnosis and treatment is important in preventing related morbidity and mortality. Pulmonary involvement is the most common form of the disease manifested in 95% of cases but onset of the disease with rare symptoms such as proptosis (in 2% of the cases) and hyperthyroidism (in 1% of the cases) has been reported as well.



Table of content

1. Presentation - Global Information

2. Diagnosis, treatment and management

3. Products

4. Products in development 
   Abatacept (Bristol-Myers Squibb) 
   Azathioprine (Bristol-Myers Squibb) 
   Etanercept (Immunex) 
   Mycophenolate mofetil

List of Tables:

Table 1: Systemic manifestations of Wegener's Granulomatosis 
Table 2: Cytotoxic medications frequently used in the treatment of Wegener's granulomatosis: strategies to monitor for and prevent toxicity 
Table 3: Clinical Trial in Recruiting Status for Wegener's Granulomatosis 
Table 4: Clinical Trial Completed for Wegener's Granulomatosis



Publication date: Number of pages: Price:
2009-11-25 18 1500 euros